JPH09510225A - バルサルタンを用いる糖尿病性ネフロパシーの治療 - Google Patents

バルサルタンを用いる糖尿病性ネフロパシーの治療

Info

Publication number
JPH09510225A
JPH09510225A JP7523813A JP52381395A JPH09510225A JP H09510225 A JPH09510225 A JP H09510225A JP 7523813 A JP7523813 A JP 7523813A JP 52381395 A JP52381395 A JP 52381395A JP H09510225 A JPH09510225 A JP H09510225A
Authority
JP
Japan
Prior art keywords
treatment
glomerular
diabetic nephropathy
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7523813A
Other languages
English (en)
Japanese (ja)
Inventor
ガスパロ，マルク ドゥ
レバンス，ニゲル
Original Assignee
チバ−ガイギー アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4195481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH09510225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by チバ−ガイギー アクチェンゲゼルシャフト filed Critical チバ−ガイギー アクチェンゲゼルシャフト
Publication of JPH09510225A publication Critical patent/JPH09510225A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP7523813A 1994-03-17 1995-03-07 バルサルタンを用いる糖尿病性ネフロパシーの治療 Pending JPH09510225A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH80094 1994-03-17
CH800/94-1 1994-03-17
PCT/EP1995/000831 WO1995024901A1 (fr) 1994-03-17 1995-03-07 Traitement de la nephropathie diabetique a l'aide de valsartan

Publications (1)

Publication Number Publication Date
JPH09510225A true JPH09510225A (ja) 1997-10-14

Family

ID=4195481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7523813A Pending JPH09510225A (ja) 1994-03-17 1995-03-07 バルサルタンを用いる糖尿病性ネフロパシーの治療

Country Status (12)

Country Link
EP (1) EP0750500A1 (fr)
JP (1) JPH09510225A (fr)
CN (1) CN1143908A (fr)
AU (1) AU1850695A (fr)
BR (1) BR9507086A (fr)
CA (1) CA2184712A1 (fr)
CZ (1) CZ268896A3 (fr)
FI (1) FI963611L (fr)
HU (1) HUT76542A (fr)
PL (1) PL316259A1 (fr)
SK (1) SK117996A3 (fr)
WO (1) WO1995024901A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010043101A (ja) * 2000-08-22 2010-02-25 Novartis Ag 組合せ

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0883401T3 (da) * 1996-02-29 2003-05-05 Novartis Ag AT1-receptorantagonist til stimulering af apoptose
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1999012534A1 (fr) * 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Regulateurs des recepteurs actives par le proliferateur des peroxisomes
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
NZ522953A (en) 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
AR032758A1 (es) 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP1454625A1 (fr) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines pour le traitement des néphropaties diabétiques
WO2005046677A2 (fr) * 2003-11-14 2005-05-26 Novartis Ag Utilisation pharmaceutique supplementaire
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
WO2010104485A2 (fr) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Préparations de valsartan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5140037A (en) * 1990-03-20 1992-08-18 E. I. Du Pont De Nemours And Company Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010043101A (ja) * 2000-08-22 2010-02-25 Novartis Ag 組合せ
JP2013049683A (ja) * 2000-08-22 2013-03-14 Novartis Ag 組合せ
JP2015205909A (ja) * 2000-08-22 2015-11-19 ノバルティス アーゲー 組合せ

Also Published As

Publication number Publication date
MX9603999A (es) 1997-12-31
SK117996A3 (en) 1997-03-05
PL316259A1 (en) 1997-01-06
FI963611A7 (fi) 1996-09-13
EP0750500A1 (fr) 1997-01-02
CN1143908A (zh) 1997-02-26
CZ268896A3 (en) 1997-03-12
BR9507086A (pt) 1997-09-16
AU1850695A (en) 1995-10-03
CA2184712A1 (fr) 1995-09-21
WO1995024901A1 (fr) 1995-09-21
HUT76542A (en) 1997-09-29
FI963611A0 (fi) 1996-09-13
FI963611L (fi) 1996-09-13
HU9602536D0 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
JPH09510225A (ja) バルサルタンを用いる糖尿病性ネフロパシーの治療
JP6612200B2 (ja) 抗炎症性の置換シクロブテンジオン化合物のコリン塩
JP2021522247A (ja) 肝疾患における好中球エラスターゼ阻害薬の使用
WO1988005656A1 (fr) Sel de sodium en cristaux anhydres de 5-chloro-3-(2-thenoyle)-2-oxindole-1-carboxamide
WO2020107500A1 (fr) Sel de 2-(1)-acyloxypentyl) acide benzoïque formé par un acide aminé basique ou aminoguanidine, son procédé de préparation et ses applications
JPS63264421A (ja) 高脂質血症治療剤
KR20090073381A (ko) 심장질환의 치료 및 예방을 위한 약제 조성물
AU2002350832B2 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
US20070249720A1 (en) Thiourea Derivative-Containing Pharmaceutical Composition Having Improved Solubility and Bioavailability
TW201206431A (en) Association of xanthine oxidase inhibitors and metformin and use thereof
KR960007752B1 (ko) 심부전증 치료제
AU2011270133B2 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
JPS61155327A (ja) ジヒドロピリジン化合物を含有する抗動脈硬化剤
CN103664930B (zh) 一类含噻唑结构的化合物、其制备方法和用途
CN109879839B (zh) 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
JPH0647540B2 (ja) 虚血性心疾患・不整脈治療・予防剤
MXPA96003999A (en) Treatment of diabetic nephropathy with valsar
JPH05262747A (ja) 潰瘍性大腸炎治療剤
TW200423972A (en) Tablet having improved solubility
WO1996025932A1 (fr) Medicament preventif et curatif, pour la pneumonie interstitielle, les maladies inflammatoires intestinales ou l'epaississement des vaisseaux, contenant des composes de quinolizinone, des sels de ces composes ou des hydrates
JP2621382B2 (ja) 尿酸排泄剤
CN116211849A (zh) 吡唑啉酮化合物在制备预防和/或治疗糖尿病心肌病的药物中的应用
JPH0377898A (ja) シアロシルコレステロールからなる筋ジストロフィー症治療剤
KR101324689B1 (ko) 1-(3-클로로페닐)-3-알킬파이퍼라진을 포함하는 식욕 장애 치료용 약학 조성물
JPH0228113A (ja) 高尿酸血症改善・治療剤